Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 53-58 , January 2010

Prevalence of dyslipidemia and its associated factors among Jordanian adults

  • Yousef S. Khader, BDS, MSc, MSPH, ScD

      Affiliations

    • Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Anwar Batieha, MD, PhD

      Affiliations

    • Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan
    • ,
  • Mohammed El-Khateeb, MD, PhD

      Affiliations

    • National Center for Diabetes, Endocrinology and Genetics, Amman, Jordan
    • ,
  • Mousa Al Omari, MRCGP

      Affiliations

    • Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan
    • ,
  • Kamel Ajlouni, MD, PhD

      Affiliations

    • National Center for Diabetes, Endocrinology and Genetics, Amman, Jordan

Received 24 August 2009 ,Accepted 14 December 2009.

References 

  1. INCLEN Multicentre Collaborative Group. Risk factors for cardiovascular disease in the developing world: A multicentre collaborative study in the International Clinical Epidemiology network (INCLEN). J Clin Epidemiol. 1992;45:841–847
  2. World Health Organization. World Health Report 2003: Shaping the Future. Geneva, Switzerland: WHO; 2003;
  3. Murrray CJ, Lopez AD. Mortality by cause for eight regions of the world; Global Burden of Disease Study. Lancet. 1997;349:1269–1276
  4. Groundy SM, Small LDL. Atherogenic dyslipidemia and the metabolic syndrome. Circulation. 1997;95:1–4
  5. Haffnar M. Diabetes, hyperlipidemia and coronary artery disease. Am J Cardiol. 1999;83(Suppl):17F–21F
  6. Wietlisbach V, Paccaud F, Rickenbach M, et al. Trends in cardiovascular risk factors (1984–1993) in a Swiss region: results of three population surveys. Prev Med. 1997;26:523–533
  7. Yamada M, Wong LF, Kodama K, et al. Longitudinal trends in total serum cholesterol levels in a Japanese cohort, 1958–1986. J Clin Epidemiol. 1997;50:425–434
  8. Hodge AM, Dowse GK, Toelupe P, et al. The association of modernisation with dyslipidemia and changes in lipid levels in the Polynesian population of Western Samoa. Int J Epidemiol. 1997;26:297–306
  9. World Health Organization. Quantifying Selected Major risks to health. In: The World Health Reports 2002—Reducing Risks, Promoting Health Life. Geneva: World Health Organization; 2002;p. 47–97
  10. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ. 2006;332:1115–1124
  11. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of Cardiovascular outcomes trials, comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445
  12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 high risk individuals. A randomized placebo-controlled trial. Lancet. 2002;360:7–20
  13. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and Safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278
  14. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardial. 2004;44:720–730
  15. Ajlouni K, Khader YS, Batieha A, et al. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications. 2008;22:317–324
  16. Khader Y, Bateiha A, El-Khateeb M, et al. High prevalence of the metabolic syndrome among Northern Jordanians. J Diabetes Complications. 2007;21:214–219
  17. Khader Y, Batieha A, Ajlouni H, et al. Obesity in Jordan: prevalence, associated factors, comorbidities, and change in prevalence over ten years. Metab Syndr Relat Disord. 2008;6:113–120
  18. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry: Report of a WHO Expert Committee. Technical Report Series. Geneva: World Health Organization; 1995;
  19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) et al. Circulation. 2002;106:3143–3421.
  20. Verschuren WM, Jacobs DR, Bioemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five year follow-up of the Seven Countries Study. JAMA. 1995;274:131–136
  21. The Health Benefits of Smoking Cessation. A report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services; 1990;DHHS publication (CDC) 90-8416
  22. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor intervention trial. Diabetes Care. 1993;16:434–444
  23. MacMahon S, Peto R, Culter J, et al. Blood pressure, Stroke and Coronary heart disease, 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774
  24. Pearson TA, Blair SN, Daniels SR, et al. for the American Heart Association Science Advisory and Coordinating Committee AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular disease. Circulation. 2002;106:388–391
  25. Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon Lipid Study. Endocrine. 2008;34:36–51
  26. Zahid N, Claussen B, Hussain A. High prevalence of obesity, dyslipidemia and metabolic syndrome in a rural area in Pakistan. Diabetes Metabol Syndr. 2008;2:13–19
  27. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207:928–934
  28. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529
  29. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605–619
  30. de Souza LJ, Souto Filho JT, de Souza TF, et al. Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro. Arq Bras Cardiol. 2003;81:249–264
  31. al-Nuaim AR, Mirdad S, al-Rubeaan K, et al. Population-based epidemiological study on characteristics of risk factors of hypercholesterolemia in Saudi Arabia. Int J Cardiol. 1997;31(62):47–54

PII: S1933-2874(09)00447-4

doi: 10.1016/j.jacl.2009.12.004

Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 53-58 , January 2010

Article Tools